How to improve the optimal cytoreductive surgery in advanced ovarian carcinoma

Table 2 Cytoreductive rates and median overall survival with a neo-adjuvant chemotherapy protocol in the management of advanced ovarian carcinoma published by different authors

Article	Year	Number	FIGO stage	Cytoreduction rate	Median OS (months)
Vergote [70]	1998	75	IIIC–IV	36%	24
Schwartz [71]	1999	59	IIIC–IV	67.8%	12.8
Ushijima [72]	2002	65	IIIC–IV	41.5%	21
Fanfani [73]	2003	73	IIIC–IV	71.2%	27
Le [74]	2005	61	IIIC	80%	41.7
Vergote [24]	2010	322	IIIC–IV	80.6%	30